|
Market Closed -
Other stock markets
|
After hours 05:25:12 am | |||
| 48.57 USD | -5.45% |
|
51.34 | +5.70% |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark | CI |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark | CI |
Business description: CRISPR Therapeutics AG
Number of employees: 393
Sales by Activity: CRISPR Therapeutics AG
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Discovering, Developing and Commercializing Therapies | 91Cr | 11.98L | 37Cr | 3.73Cr | 35.1L |
Executive Committee: CRISPR Therapeutics AG
| Manager | Title | Age | Since |
|---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 47 | 01/12/2017 |
Raju Prasad
DFI | Director of Finance/CFO | 42 | 14/03/2023 |
Naimish Patel
CTO | Chief Tech/Sci/R&D Officer | - | 28/05/2024 |
Stephen Kennedy
CTO | Chief Tech/Sci/R&D Officer | 69 | 01/10/2019 |
Susan Kim
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: CRISPR Therapeutics AG
| Director | Title | Age | Since |
|---|---|---|---|
Simeon George
BRD | Director/Board Member | 49 | 29/04/2015 |
Ali Behbahani
BRD | Director/Board Member | 49 | 01/04/2015 |
Samarth Kulkarni
CHM | Chairman | 47 | 15/09/2023 |
Katherine High
BRD | Director/Board Member | 74 | 11/06/2019 |
John Greene
BRD | Director/Board Member | 60 | 11/06/2019 |
Doug Treco Treco
BRD | Director/Board Member | 68 | 11/06/2020 |
Harold Fleming
BRD | Director/Board Member | 63 | 10/06/2021 |
Maria Fardis
BRD | Director/Board Member | 58 | 09/06/2022 |
Christian Rommel
BRD | Director/Board Member | 59 | 13/03/2024 |
Sandy Mahatme
BRD | Director/Board Member | 61 | 30/05/2024 |
Company details: CRISPR Therapeutics AG
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.45% | -13.79% | -11.92% | -14.65% | 505.91Cr | |
| -1.07% | -1.27% | +0.95% | +5.66% | 5.03TCr | |
| -2.85% | -6.25% | +366.61% | +572.09% | 3.92TCr | |
| +1.98% | +4.82% | +13.71% | +61.68% | 3.46TCr | |
| +1.78% | +0.73% | +32.68% | -4.80% | 3.45TCr | |
| +0.06% | +1.56% | +4.41% | +27.42% | 2.7TCr | |
| -3.27% | -5.67% | - | - | 1.67TCr | |
| +1.64% | +0.45% | +70.86% | +121.18% | 1.51TCr | |
| +0.29% | +1.02% | +14.95% | +17.80% | 1.39TCr | |
| -1.21% | +0.73% | +18.02% | -30.96% | 1.32TCr | |
| Average | -0.81% | -1.22% | +56.70% | +83.93% | 2.5TCr | |
| Weighted average by Cap. | -0.41% | +0.14% | +75.56% | +116.01% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRSP Stock
- Company CRISPR Therapeutics AG
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition